NEW YORK (GenomeWeb) – EKF Diagnostics recently announced that its board of directors has initiated a strategic review, to be led by an independent committee of non-executive directors consisting of Adam Reynolds, David Toohey, Doris Ann Williams, and chaired by Kevin Wilson.
The review was initiated at the suggestion of shareholders and is being done to explore all strategic options available to ensure shareholder value, a spokesperson for the firm told GenomeWeb in an email.
"The strategic review is looking at all options for the company. Spinning out the molecular diagnostics business could be one of those options, but it would be premature to predict the outcome of the review," the spokesperson said.
In September 2014 EKF Diagnostics entered into a collaboration with Massachusetts General Hospital to develop assays to detect cancer mutations.